TKI discontinuation clinical trials

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients

This study looks at whether people with Chronic Myeloid Leukemia (CML) can successfully stop their nilotinib medicine a second or third time if their cancer has been well-controlled for a long time. It focuses on those who previously tried and weren't able to stop permanently.